IL6 and COVID-19: Thus, a major finding by Durstenfeld et al. [38] was that IL-6 was elevated among most of those with post-acute sequelae of COVID-19, with higher levels in women and in those with the central sensitization phenotype (e.g., fatigue, pain, depression, and anxiety) compared with the cardiopulmonary phenotype.